NCT07747480
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 31 words
- Primary and study completion dates moved earlier to Mar 5, 2028
- Study sites: 0 to 1
- Start date changed from estimate of Aug 10, 2026 to Sep 3, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants with Adverse events (AEs)
Timeframe: Up to 34 weeks [End of sub-study (EOSS)]
Number of Participants with Serious AEs (SAEs)
Timeframe: Up to 34 weeks (EOSS)
Number of Participants who Discontinue Study Intervention due to AEs
Timeframe: Up to 34 weeks (EOSS)
Number of Participants with Clinically Significant Changes in Laboratory Readings
Timeframe: Up to 34 weeks (EOSS)
Number of Participants with Clinically Significant Changes in Vital Signs
Timeframe: Up to 34 weeks (EOSS)
Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Readings
Timeframe: Up to 34 weeks (EOSS)
Arms and interventions
Aletekitug (GSK1070806)Experimental
Participants will receive Aletekitug.
Biologicals: Aletekitug
Sites
1 site in 1 country
- GSK Investigational SiteOxford, United Kingdom